Jeff Yass’s DiaMedica Therapeutics DMAC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-21,650
Closed -$147K 13611
2026
Q1
$147K Sell
21,650
-22,736
-51% -$180K ﹤0.01% 12033
2025
Q4
$353K Buy
44,386
+16,019
+56% +$120K ﹤0.01% 9564
2025
Q3
$195K Sell
28,367
-4,429
-14% -$24K ﹤0.01% 11024
2025
Q2
$128K Sell
32,796
-523,797
-94% -$2.04M ﹤0.01% 11623
2025
Q1
$2.11M Buy
556,593
+181,748
+48% +$1.04M ﹤0.01% 5414
2024
Q4
$2.04M Buy
374,845
+273,395
+269% +$1.29M ﹤0.01% 5277
2024
Q3
$425K Buy
101,450
+58,077
+134% +$214K ﹤0.01% 8861
2024
Q2
$128K Sell
43,373
-165,959
-79% -$455K ﹤0.01% 10845
2024
Q1
$580K Buy
209,332
+181,713
+658% +$528K ﹤0.01% 8151
2023
Q4
$78.4K Buy
+27,619
New +$68.3K ﹤0.01% 11489
2023
Q3
Sell
-16,923
Closed -$73.1K 12181
2023
Q2
$73.1K Buy
+16,923
New +$41.1K ﹤0.01% 11152
2022
Q4
Sell
-35,258
Closed -$44K 12663
2022
Q3
$44K Buy
+35,258
New +$55.1K ﹤0.01% 12279
2022
Q2
Sell
-16,324
Closed -$38.1K 13075
2022
Q1
$41K Buy
16,324
+2,259
+16% +$6.41K ﹤0.01% 12391
2021
Q4
$52K Sell
14,065
-46,364
-77% -$182K ﹤0.01% 12521
2021
Q3
$242K Buy
60,429
+13,264
+28% +$50.8K ﹤0.01% 11076
2021
Q2
$210K Buy
+47,165
New +$387K ﹤0.01% 11504

Other funds holding DMAC

Jeff Yass's DMAC Position: Q2 2026 in Review

Jeff Yass sold out of DiaMedica Therapeutics (DMAC) in Q2 2026, closing a stake of 21,650 shares — an estimated $147K sold.

Jeff Yass first reported a position in DMAC in Q2 2021 and held it in 16 quarters. The position peaked at $2.11M in Q1 2025. 88 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Jeff Yass reported no remaining DiaMedica Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 21,650 DiaMedica Therapeutics shares in Q2 2026, an estimated $147K.
  • Jeff Yass first reported a position in DiaMedica Therapeutics in Q2 2021 and held it in 16 quarters.
  • Jeff Yass's DiaMedica Therapeutics position peaked at $2.11M in Q1 2025.
  • 88 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.